[go: up one dir, main page]

ES2113636T3 - Trioles sustituidos. - Google Patents

Trioles sustituidos.

Info

Publication number
ES2113636T3
ES2113636T3 ES94902722T ES94902722T ES2113636T3 ES 2113636 T3 ES2113636 T3 ES 2113636T3 ES 94902722 T ES94902722 T ES 94902722T ES 94902722 T ES94902722 T ES 94902722T ES 2113636 T3 ES2113636 T3 ES 2113636T3
Authority
ES
Spain
Prior art keywords
substituted
triols
substituted triols
medicaments
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902722T
Other languages
English (en)
Inventor
Rolf Angerbauer
Peter Fey
Walter Hubsch
Thomas Philipps
Hilmar Bischoff
Hans-Peter Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2113636T3 publication Critical patent/ES2113636T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/36—Polyhydroxylic alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A TRIOLOS SUSTITUIDOS DE LA FORMULA DR, EN DONDE R ES UN RESTO DE LAS FORMULAS (A), (B), (C) O (D) PUDIENDO SER UTILIZADA COMO SUSTANCIA ACTIVA EN MEDICAMENTOS PARA TRATAMIENTO DE HIPERPROTEINEMIA.
ES94902722T 1992-12-21 1993-12-08 Trioles sustituidos. Expired - Lifetime ES2113636T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4243279A DE4243279A1 (de) 1992-12-21 1992-12-21 Substituierte Triole

Publications (1)

Publication Number Publication Date
ES2113636T3 true ES2113636T3 (es) 1998-05-01

Family

ID=6475975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902722T Expired - Lifetime ES2113636T3 (es) 1992-12-21 1993-12-08 Trioles sustituidos.

Country Status (11)

Country Link
US (2) US5861385A (es)
EP (1) EP0674638B1 (es)
JP (1) JPH08505375A (es)
KR (1) KR950704315A (es)
AT (1) ATE164159T1 (es)
AU (1) AU5697994A (es)
CA (1) CA2152056A1 (es)
DE (2) DE4243279A1 (es)
ES (1) ES2113636T3 (es)
HU (1) HUT72082A (es)
WO (1) WO1994014807A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
SV2005001973A (es) 2003-12-12 2005-11-04 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
CA2590533C (en) 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
HUE035130T2 (en) 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv A method for preparing compounds useful as SGLT inhibitors
WO2009102761A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
DK2451797T3 (da) 2009-07-10 2013-06-24 Janssen Pharmaceutica Nv Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen
EP2488515B1 (en) * 2009-10-14 2017-01-04 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt2
TWI599360B (zh) 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
RS55056B1 (sr) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US4440927A (en) * 1981-06-19 1984-04-03 Merck & Co., Inc. Process for preparing inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase via a chiral synthon
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
WO1984002131A1 (fr) * 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4973704A (en) * 1985-10-25 1990-11-27 Sandoz Pharm. Corp. Pyrrolyl intermediates in the synthesis of pyrrole analogs of mevalonolactone and derivatives thereof
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4927851A (en) * 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
NO881411L (no) * 1987-04-14 1988-10-17 Bayer Ag Substituerte pyrroler.
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
ES2082755T3 (es) * 1987-07-10 1996-04-01 Hoechst Ag Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios.
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US4997837A (en) * 1987-09-08 1991-03-05 Warner-Lambert Company 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
JPH01242570A (ja) * 1988-01-27 1989-09-27 May & Baker Ltd イソキノリノン類
NO890988L (no) * 1988-03-24 1989-09-25 Bayer Ag Disubstituerte pyrroler.
CA2016690C (en) * 1989-06-07 1994-03-08 William T. Osborne Cooling system with supplemental thermal storage
US5072002A (en) * 1989-07-18 1991-12-10 The Governors Of The University Of Alberta Synthesis of cholesterol-lowering agents
JP2520491B2 (ja) * 1989-12-12 1996-07-31 キヤノン電子株式会社 光学機器
CA2043525A1 (en) * 1990-06-24 1991-12-25 Donald S. Karanewsky Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
DE4022414A1 (de) * 1990-07-13 1992-01-16 Bayer Ag Substituierte pyrrolo-pyridine
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5298625A (en) * 1992-12-07 1994-03-29 E. R. Squibb & Sons, Inc. Process for the preparation of 4-phosphinyl-3-keto-carboxylate and 4-phosphonyl-3-keto-carboxylate intermediates useful in the preparation of phosphorus containing HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
US5861385A (en) 1999-01-19
HUT72082A (en) 1996-03-28
CA2152056A1 (en) 1994-07-07
JPH08505375A (ja) 1996-06-11
DE4243279A1 (de) 1994-06-23
EP0674638B1 (de) 1998-03-18
HU9501799D0 (en) 1995-08-28
ATE164159T1 (de) 1998-04-15
DE59308292D1 (de) 1998-04-23
EP0674638A1 (de) 1995-10-04
US6277833B1 (en) 2001-08-21
WO1994014807A1 (de) 1994-07-07
KR950704315A (ko) 1995-11-17
AU5697994A (en) 1994-07-19

Similar Documents

Publication Publication Date Title
ATE164159T1 (de) Substituierte triole
NO940277L (no) Triglycerider og blandinger av slike
DE58904042D1 (en) Substituierte 4-(chinolin-2-yl-methoxy)phenyl-essigsaeure-derivate.
DE68919146D1 (de) Ausgewählte Stämme von Lactobacillus enthaltende pharmazeutische Zusammensetzungen.
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
MY109880A (en) Substituted biphenylpyridones
MY104685A (en) Substituted thiazoles and their use as fungicides.
NZ216657A (en) N-buten-3-yl-azaheterocyclic carboxylic acid compounds and pharmaceutical compositions
GR3023235T3 (en) Hydrogele prepared by using Alkenyl-phosphonic and phosphinic acid esters as cross-linking agents.
ATE85606T1 (de) Carbaminsaeureester, verwendbar als mikrobicid und konservierungsmittel.
DE3851644D1 (de) Graphischer Anzeigeregler mit Begrenzungsfunktion.
DE59300135D1 (de) Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone.
DE59002546D1 (de) Anhebbares Doppelachsaggregat.
DE68924624D1 (de) Leistungssparender NF-Leistungsverstärker.
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
EP0325129A3 (en) Disubstituted pyridines
CA2063127A1 (en) Reduction in cutaneous atrophy
ATE99310T1 (de) Substituierte 1,8-naphthyridine.
FI890729A0 (fi) Anordning foer montering av delarna i en vinkelremledning.
FI923968A0 (fi) Heterocykliskt substituerade kinolylmetoxifenylacetamider.
ATE63684T1 (de) Deodorant.
DK0610697T3 (da) Imidazolyl-substituerede phenyleddikesyreprolinamider.
ATE160146T1 (de) Hetero-tricyclisch-substituierte phenyl- cyclohexan-carbonsäurederivate
FI931887A7 (fi) Nestemäisiä koostumuksia, jotka sisältävät karboksyyliestereitä
NO912681D0 (no) Anordning for sammenfoeyning av delkomponenter i moebler.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674638

Country of ref document: ES